A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge

Infection and Immunity

Volumn 64, Issue 5, 1996, Pages 1659-1665

  Fattom, Ali I ^a   Sarwar, Jawad ^a   Ortiz, Alberto ^a   Naso, Robert ^a  

^a Nabi Biopharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; EXOPROTEIN A; IMMUNOGLOBULIN G; MUCIN; PERITONEAL DIALYSIS FLUID; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; FEMALE; INFECTION PREVENTION; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY PARENCHYMA; LIVER; MORTALITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BACTEREMIA; BACTERIAL CAPSULES; BACTERIAL VACCINES; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; POLYSACCHARIDES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VACCINATION; VIRULENCE;

EID: 0029933430     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.5.1659-1665.1996     Document Type: Article

References (66)

1. Albus, A., R. D. Arbeit, and J. C. Lee. 1991 Virulence of Staphylococcus aureus mutants altered in type 5 capsule production Infect. Immun. 59:1008-1014.
2. Albus, A., J.-M. Fournier, C. Wolz, A. Boutonnier, M. Ranke, N. Hoiby, H. Hochkeppel, and G. Doring. 1988. Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis J. Clin Microbiol 26:2505-2509.
3. Arbeit, R., and R. M. Dunn. 1987 Expression of capsular polysaccharide during experimental focal infections with Staphylococcus aureus. J. Infect. Dis. 156:947-952
4. Arbeit, R., W. W. Karakawa, W. F. Vann, and J. B. Robbins. 1984 Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn. Microbiol Infect. Dis. 2:85-91.
5. Arbeit, R., and M. J. Nelles. 1987 Capsular polysaccharide antigenemia in rats in experimental endocarditis due to Staphylococcus aureus. J. Infect. Dis. 135:242-246.
6. Baddour, L. M., C. Lowrance, A. Albus, J. H. Lowrance, S. K. Anderson, and J. C. Lee. 1992. Staphylococcus aureus microcapsule expression attenuates bacterial virulence in rat model of experimental endocarditis. J. Infect. Dis. 165:749-753.
7. 6a.Bayer, A. Unpublished data.
8. Boutonnier, A., F. Nato, A. Bouvet, L. Lebrun, A. Audrier, J. C. Mazie, and J.-M. Fournier. 1989. Direct testing of blood cultures for detection of the serotype 5 and 8 capsular polysaccharides of Staphylococcus aureus J. Clin. Microbiol. 27:989-994.
9. Bryant, R. E., J. P. Sanford, and A. Alcoze. 1965. Treatment of recurrent furunculosis with staphylococcal bacteriophage-lysed vaccine. JAMA 194:11-14.
10. Dassy, B., W. T. Stringfellow, M. Lieb, and J.-M. Fournier. 1993. Production of type 5 capsular polysaccharide by Staphylococcus aureus grown in semisynthetic medium. J. Gen. Microbiol. 137:1155-1162.
11. Daum, R. S., A. Fattom, S. Freesa, and W. W. Karakawa. 1994. Capsular polysaccharide serotypes of coagulase-positive staphylococci associated with tenosynovotis, osteomyelitis, and other invasive infections in chicken and turkeys: evidence for new capsular types. Avian Dis. 38:762-771
12. Dillenberg, H. 1962. Experience with a polyvalent staphylococcal vaccine with alpha-toxoid. Can J. Public Health 53:248-253.
13. Dillenberg, H., and M. P. D. Waldron. 1963 A preventive approach to impetigo of treaty Indians using a staphylococcus polyvalent somatic antigen vaccine. Can. Med. Ass. J. 89:947-949.
14. Ekstedt, R. D. 1974 Immune response to surface antigens of S. aureus and their role in resistance to staphylococcal disease. Ann. N.Y. Acad. Sci. 236:203-220.
15. 13a.Fattom, A. Unpublished data.
16. Fattom, A., R. Schneerson, W. W. Karakawa, D. Fitzgerald, I. Pastan, X. Li, J. Shiloach, D. A. Bryla, and J. B. Rohhins. 1993. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus types 5 and 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. immun. 61:1023-1032.
17. Fattom, A., R. Schneerson, S. S. Szu, W. F. Vann, J. Shiloach, and J. B. Robbins. 1990. Synthesis and immunologic properties in mice of vaccines composed of Siaphylococcus aureus type 5 and type S capsular polysaccarides conjugated to Pseudomonas aeruginosa exotoxin A. Infect. Immun 58:2367-2374.
18. Fattom, A., J. Shiloach, D. Bryla, D. Fitzgerald, I. Pastan, W. W. Karakawa, J. B. Robbins, and R. Schneerson. 1992. Comparative immunogenicity of conjugates composed of S aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyi-3-(2-pyridyldithio) propionate. Infect. Immun. 60:584-589.
19. Fisher, M. W., H. B. Devlin, and A. L. Eriandson. 1963. A new staphylococcai antigen. Nature (London) 199:1074-1075.
20. Fisher, S. 1961. Observation on an antistaphylococcal mouse protective antibody in human sera. Aust. J. Exp. Biol. 39:413-422.
21. Foster, T. J. 1991 Potential for vaccination against infections caused by Staphylococcus aureus. Vaccine 9:221-226.
22. Fournier, J.-M. 1991. Staphylococcus aureus, p 166-177. In S J. Cryz, Jr. (ed.). Vaccine and immunotherapy Pergamon Press, New York.
23. Fournier, J.-M., K. Hannon, M. Moreau, W. W. Karakawa, and W. F. Vann. 1987. Isolation of type 5 capsular polysaccharide from Staphylococcus aureus. Ann. Inst. Pasteur/Microbiol. (Paris) 138:561-567.
24. Fournier, J.-M., W. F. Vann, and W. W. Karakawa. 1984. Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide. Infect. Immun. 45:87-93.
25. Greenberg, D. P., J. I. Ward, and A. S. Bayer. 1987. Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits. Infect. Immun. 55:3030-3034.
26. Greenberg, L., and M. Y. Cooper. 1960. Polyvalent somatic antigen for the prevention of staphylococcal infections. Can. Med. Assoc. J. 83:143-147.
27. Greenberg, L., and W. H. Le Riche. 1961. Staphylococcal enzyme lysed soluble vaccine. Can J. Public Health 52:479-485.
28. Heidelberger, M., and C. F. McPhearson. 1943. Quantitative micro-estimation of antibodies in the sera of man and other animals. Science 97:405-406.
29. Hochkeppel, H. K., D. G. Braun, W. Vischer, A. Imm, S. Sutter, U. Staeubli, R. Guggenheim, E. L. Kaplan, A. Boutonnier, and J.-M. Fournier. 1987. Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8. J. Clin. Microbiol. 25:526-530.
30. Karakawa, W. W., J. M. Fournier, W. F. Vann, R. Arbeit, R. S. Schneerson, and J. B. Robbins. 1985. Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin. Microbiol. 22:445-447.
31. Karakawa, W. W., A. Sutton, R. Schneerson, A. Karpas, and W. F. Vann. 1988. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect. Immun 56:1090-1095
32. Karakawa, W. W., and W. F. Vann. 1982. Capsular polysaccharides of Staphylococcus aureus. Semin. Infect Dis. 4:285-293.
33. Karakawa, W. W., and W. F. Vann. 1982. Capsular polysaccharides of Staphylococcus aureus, p. 285-293. In L. Weinstein and B. N. Fields (ed.), Seminars in infectious disease. Thieme-Stratton, New York.
34. Kenne, L., and B. Lindbergh. 1984. Bacterial polysaccharides Poiysaccharides 2:262-290.
35. Koenig, M. G. 1962 Factors relating to the virulence of staphylococci. L Comparative studies of two colonial variants. Yale J. Biol. Med. 34:537-559.
36. Koenig, M. G., and M. A. Melly. 1965. The importance of surface antigens in staphylococcal virulance. Ann. N Y Acad. Sci. 128:231-250.
37. Krause, R. M. 1989. Immunity to Staphylococcus aureus, a persistent enigma. Emory Univ. J. Med. 3:77-85.
38. 35a Lee, J. Unpublished data.
39. Lee, J. C., M. J. Betley, C. A. Hopkins, N. E. Perez, and G. B. Pier. 1987. Virulence studies, in mice, of transposon-induced mutant of Staphylococcus aureus differing in capsular size. J. Intect. Dis. 156:751-750.
40. Lee, J. C., N. E. Perez, C. A. Hopkins, and G. B. Pier. 1988. Purified capsular polysaccharide-mduced immunity to Staphylocaccus aureus infection. J. Infect. Dis 157:723-730.
41. Lee, J. C., S. Takeda, P. J. Livolsi, and L. C. Paoletti. 1993. Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus. Infect. Immun. 61:1853-1858.
42. Manclark, C. R., B. D. Meade, and D. G. Burstyn. 1986. Serological response to Bordetella pertussis,.p. 388-394. In N. R. Rose, H Friedman, and J. L. Fahey (ed.). Manual of clinical laboratory immunology American Society for Microbiology, Washington, D.C.
43. Melly, M. A., L. J. Duke, D. F. Liau, and J. H. Hash. 1974. Biological properties of encapsulated Staphylococcus aureus M. Infect. Immun. 10:389-397.
44. Melly, M. A., Z. A. McGee, R. G. Horn, F. Morris, and A. D. Glick. 1979. An electron microscopic India ink technique for demonstrating capsules on microorganisms: studies with 5 pneumonia, S aureus, and N. gonorrhoeae. J. Infect. Dis. 140:605-609.
45. Moreau, M., J. C. Richards, J.-M. Fournier, R. A. Byrd, W. W. Karakawa, and W. F. Vann. 1990 Structure of the type 5 capsular polysaccharide of Staphylococcus aureus. Carbohydr. Res. 201:285-297.
46. Morse, S. 1965 Staphylococci and other micrococci, p. 412-439 In R. J. Dubos and J. G. Hirsch (ed), Bacterial and mycotic infection of man. J. B. Lippincott Company, Philadelphia
47. Nemeth, J., and J. C. Lee. 1995. Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis. Infect. Immun. 63:375-380.
48. Peterson, P. K., B. J. Wilkinson, Y. Kim, D. Schmeling, and P. G. Quie. 1978 Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect. Immun. 19:943-949.
49. Poutrel, B., A. Boutonnier, L. Sutra, and J.-M. Fournier. 1988 Prevalence of capsular polysaccharide types 5 and 8 among Staphylococcus aureus isolates from cow, goat, and ewe milk. J. Clin. Microbiol. 26:38-40.
50. Poutrel, B., F. B. Gilbert, and M. Lebrun. 1995. Effects of culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strains. Clin Diagn. Lab. Immunol 2:166-171.
51. Poutrel, B., and L. Sutra. 1993. Type 5 and 8 capsular polysaccharides are expressed by Staphylococcus aureus isolates from rabbits, poultry, pigs, and horses. J. Clin. Microbiol. 31:467-469.
52. Quie, P. G. 1972. Bactericidal function of human polymorpbonuclear leukocytes. Pediatrics 50:264-270.
53. Robbins, J. B., and R. Schneerson. 1990. Polysacchande-protein conjugates. A new generation of vaccines. J. Infect Dis. 161:821-832.
54. Robbins, J. B., R. Schneerson, W. B. Egan, W. F. Vann, and D. T. Liu. 1980. Virulence properties of bacterial capsular polysaccharides - unanswered questions, p 115-132 In H. Smith, J. J. Skehel, and M J Turner (ed.), The molecular basis of microbial pathogenicity Dahlen Konferenzen, Verlag Chemie GmbH, Weinheim, Germany.
55. Rogers, D. E., and M. A. Melly. 1965. Speculation on the immunology of staphylococcal infection. Ann. N. Y. Acad. Sci. 128:274-284.
56. Salmon, G. G., Jr., and M. Symonds. 1963. Staphage lysate therapy in chronic staphyloccocal infections. J. Med. Assoc. N.J. 60:188-193
57. Schneerson, R., O. Barrera, A. Sutton, and J. B. Robbins. 1980. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:361-376.
58. Stringfellow, W. T., B. Dassy, M. Lieb, and J.-M. Fournier. 1991. Staphylococcus aureus growth and type 5 capsular polysaccharide production in synthetic media. Appl. Environ. Microbiol 57:618-621
59. Sutra, L., C. Mendolia, P. Ralnard, and B. Poutrel. 1990. Encapsulation of Staphylococcus aureus isolates from mastitic milk: relationship between capsular polysaccharide types 5 and 8 and colony morphology in serum-soft agar, clumping factor, teichoic acid, and protein A. J Clin. Microbiol. 28:447-451.
60. Sutra, L., P. Rainard, and B. Poutrel. 1990. Phagocytosis of mastitis isolates of Staphylococcus aureus and expression of type 5 capsular polysaccharide are influenced by growth in the presence of milk J Clin. Microbiol 28:2253-2258
61. Sutton, A., W. F. Vann, A. Karpas, K. A. Stein, and R. Schneerson. 1985. An avidin-biotin-based ELISA for quantitation of antibody to bacterial polysaccharides J. Immunol. Methods 82:215-224.
62. Wright, A. E., and S. R. Douglas. 1904 An experimental investigation of the role of fluids in connection with phagocytosis. Proc. R. Soc. Lond. 73:128-142.
63. Xu, S., R. D. Arbeit, and J. C. Lee. 1992 Phagocytic killing of encapsulated Staphylococcus aureus by human polymorphonuclear lymphocytes. Infect. Immun. 60:1358-1362.
64. Yoshida, K., Y. Ichiman, S. Narikawa, and W. B. Evans. 1984. Staphylococcal capsular vaccine for preventing mastitis in two herds in Georgia J. Dairy Sci. 67:620-627.
65. Yoshida, K., Y. Ichiman, S. Narikawa, M. Takahashi, E. Kono, and C. L. San Clemente. 1979. Passive protection by human serum in mice infected with encapsulated Staphylococcus aureus. J. Med Microbiol. 12:277-282.
66. Zollinger, W. D., and J. W. Boslego. 1981 A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J. Immunol. Methods 46:129-140.